Clinical Cancer Research, Vol 4, Issue 9 2253-2256, Copyright © 1998 by American Association for Cancer Research

ARTICLES

Toxicity and dose-response studies of 1,25-(OH)2-16-ene-23-yne vitamin D3 in transgenic mice

CL Wilkerson, SR Darjatmoko, MJ Lindstrom and DM Albert
Department of Ophthalmology and Visual Sciences, University of Wisconsin Medical School, Madison 53792-3220, USA.

The vitamin D3 analogue 1,25-(OH)2-16-ene-23-yne vitamin D3 (16,23-D3) in doses with low systemic toxicity has been demonstrated to inhibit retinoblastoma growth in transgenic mice. This study examines the dose-dependent response for inhibition of tumor growth in transgenic mice with retinoblastoma and evaluates the in vivo toxicity of 16,23-D3 in nontransgenic mice. Transgenic 8-10-week-old mice with retinoblastoma (n = 119) were randomly assigned to groups receiving 1.0, 0.75, 0.5, 0.35, 0.2, or 0.05 microg of 16,23-D3 and a vehicle alone (control) group i.p. five times a week for 5 weeks. An additional control group received no injection. Eyes were enucleated one week after the end of treatment, and tumor areas were measured. To determine the toxic dose, transgene-negative littermates received 0.5, 1.0, 1.5, 2.5, 3.5, 4.5, or 5.0 microg of 16,23-D3, and control groups received vehicle alone, 5 days a week for 5 weeks. Serum calcium levels were measured, and necropsies were performed on animals from each group. In the dose-response study, tumor growth inhibition was greatest in the group receiving 0.35 microg (55% inhibition; P = 0.0056) and was also significant in the group receiving 0.5 microg (42% inhibition; P = 0.036). The systemic toxic effects due to hypercalcemia occurred at doses of > or =1.0 microg. 16,23-D3 inhibits tumor growth at doses > or =0.35 microg and shows toxic effects at doses > or =1.0 microg related to hypercalcemia in mice fed an unrestricted diet. No toxicity was observed with lower doses.

This article has been cited by other articles:

				D. M. Albert, A. Kumar, S. A. Strugnell, S. R. Darjatmoko, J. M. Lokken, M. J. Lindstrom, and S. Patel Effectiveness of Vitamin D Analogues in Treating Large Tumors and During Prolonged Use in Murine Retinoblastoma Models Arch Ophthalmol, September 1, 2004; 122(9): 1357 - 1362. [Abstract] [Full Text] [PDF]

				D. M. Albert, A. Kumar, S. A. Strugnell, S. R. Darjatmoko, J. M. Lokken, M. J. Lindstrom, C. M. Damico, and S. Patel Effectiveness of 1{alpha}-Hydroxyvitamin D2 in Inhibiting Tumor Growth in a Murine Transgenic Pigmented Ocular Tumor Model Arch Ophthalmol, September 1, 2004; 122(9): 1365 - 1369. [Abstract] [Full Text] [PDF]

				R. J. Grostern, P. J. Bryar, M. L. Zimbric, S. R. Darjatmoko, B. J. Lissauer, M. J. Lindstrom, J. M. Lokken, S. A. Strugnell, and D. M. Albert Toxicity and Dose-Response Studies of 1{alpha}-Hydroxyvitamin D2 in a Retinoblastoma Xenograft Model Arch Ophthalmol, May 1, 2002; 120(5): 607 - 612. [Abstract] [Full Text] [PDF]

				S. J. Sabet, S. R. Darjatmoko, M. J. Lindstrom, and D. M. Albert Antineoplastic Effect and Toxicity of 1,25-Dihydroxy-16-ene-23-yne-vitamin D3 in Athymic Mice With Y-79 Human Retinoblastoma Tumors Arch Ophthalmol, March 1, 1999; 117(3): 365 - 370. [Abstract] [Full Text] [PDF]